Patients with metastatic non small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry …

Purpose: Guidelines for stage IV NSCLC recommend stratified treatment by biomarker test results. We used CRISP to evaluate treatment and outcome of patients (pts) with targetable molecular alterations. Methods: Currently 163 sites in Germany have recruited> 4255 pts at start of 1st-line who will be followed until death or end of project. Data from 2204 pts recruited by 133 sites from 12/2015 to 06/2018 was analyzed. Progression-free survival (PFS) was determined in pts observed≥ 1 year (recruited< 06/2017 (n= 906), outcome sample (ous)).Results: 94%/65% of 1732/472 pts with non-squamous/squamous tumors were tested for any biomarker. In 2018 test rate was 96%/75% and 49%/33% were tested for all biomarkers (EGFR, ALK, ROS1, BRAF) with approved targeted therapies (aTT). An alteration in EGFR, ALK, ROS1 or BRAF was detected in 9%, 3%, 2%, and 2% of pts, respectively. Of pts with druggable …